EMEA-002506-PIP03-21
Key facts
| Active substance |
Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin (tosatoxumab)
|
| Therapeutic area |
|
| Decision number |
P/0563/2021
|
| PIP number |
EMEA-002506-PIP03-21
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Staphylococcus aureus pneumonia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Aridis Pharmaceuticals Inc
Email: mmscltd@gmail.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|